Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

Blog Article

After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan.Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential davis oatmeal and aloe shampoo risk factors.The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor.To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database.The adherence to the recommended dosing of SU co-prescribed with DPP-4 inhibitors increased from 46.

3% before to 63.8% after the JADEC recommendation (p < 0.01 by time-series analysis), while no change was found in those for SU monotherapy and SU with other OHD co-prescriptions.The adherence was significantly worse for those receiving a glibenclamide prescription.The JADEC recommendation, along with labeling changes, appeared to have a favorable effect on the risk minimization action in Japan.

In these instances, a pharmacy claims maybelline green concealer database can be a useful tool to evaluate risk minimization actions.